Pharmacological Regulation of Fat Transport in Metabolic Syndrome

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine whether atorvastatin and fenofibrate are effective in the treatment of lipid disorders in obese, insulin resistant subjects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Western Australia
• Collaborator: National Heart Foundation, Australia
• Treatments: Atorvastatin; Atorvastatin Calcium; Fenofibrate

Criteria

Inclusion Criteria:

any three of the followings

• waist circumference >102cm

• triglycerides >1.7 mmol/L

• HDL-cholesterol <1.05 mmol/L

• blood glucose >6.1 mmol/L

• blood pressure >130/85mmHg

Exclusion Criteria:

• plasma cholesterol >7mmo/L

• triglycerides >4.5mmo/L

• diabetes mellitus (defined by oral glucose tolerance test)

• CVD

• consumption of >30g alcohol/day

• use of agents affecting lipid metabolism

• APOE2/E2 genotype, macroproteinuria

• creatinaemia (>120umol/L)

• hypothyroidism

• abnormal liver and muscle enzymes.